Trump Administration Halts Medicare and Medicaid Coverage for Anti-Obesity Medications
• The Trump administration has rejected a Biden-era proposal that would have provided Medicare and Medicaid coverage for anti-obesity medications to over 7 million Americans.
• Despite the high cost barrier—with drugs like Wegovy priced at nearly $1,350 for a four-week supply—CMS did not provide specific reasoning for the decision but indicated it may reconsider coverage after further review.
• Medicare will continue covering these medications for specific conditions like heart disease, while 13 states currently offer coverage through their Medicaid programs for obesity treatment.
© Copyright 2025. All Rights Reserved by MedPath